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Abstract 
Introduction: Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common 
chronic liver disease in children and adults, outpacing alcoholic and viral liver 
disease in recent years. NAFLD has been linked to obesity, diabetes and the 
metabolic syndrome (MetS). Adverse health outcomes include cardiovascular 
disease, liver cirrhosis, and liver cancer.  Prevalence of NAFLD is increasing in all 
ages but reasons remain unclear. 
Aim: To determine which individual MetS components and related disturbances 
(e.g., elevated uric acid and insulin resistance) are linked to NAFLD, and if these 
relationships varied by age (adolescents vs adults). 
Methods: Data from the National Health and Nutrition Examination Survey 
(NHANES) collected in 2001-2006 (n=12,248) were analyzed. Outcome variable 
was >30 u/L of the liver enzyme aminotransferase (ALT), a surrogate marker of 
NAFLD in lieu of the Gold Standard liver biopsy or imaging. Independent variables 
were: five MetS components and other NAFLD-related risk factors. We conducted 
multivariate Binary Logistic Regression of these study variables adjusted for 
education level, race, age, sex, and physical activity.  
Results: In adults (20+ years), high uric acid was associated with a three-fold 
likelihood of having NAFLD (OR=3.64, 95% CI 2.89-4.59). Compared to 
participants with a college degree, those who completed some college or some 
high school had higher risks of NAFLD (OR=1.32 95% CI 1.03-1.69; OR=1.33, 
95% CI 1.01-1.68; respectively). In adolescents (12-19 years), high uric acid also 
was associated with NAFLD (OR=3.46, 95% CI 2.48-4.83) as were black 
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adolescents (OR=1.20, 95% CI 1.003-1.44). For all ages, MetS individual 
components were not significantly associated with NAFLD nor was physical 
inactivity, or obesity. 
Conclusion: Our study adds novel population-based evidence that social factors 
were associated with NAFLD. Specifically, NAFLD was relatively more prominent 
in black adolescents and, in adults, with less than a college degree. The three-fold 
greater prevalence of elevated uric acid in both age groups warrants further 
research and might have translational value for screening for liver disease.  
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INTRODUCTION 
Overview. Nonalcoholic fatty liver disease is considered the hepatic component 
of the metabolic syndrome even though it is not yet part of the clinical definition.  
The concept of this form of liver disease was first introduced in 1980 when a group 
of physicians in Mayo clinic described biopsy findings of 20 patients that mimic 
alcoholic hepatitis, however, the cause was unknown. Histological findings ranged 
from fatty infiltrates in liver cells, to inflammation and necrosis in the lobules, to 
frank cirrhosis in a few patients. Most of these patients were obese and many had 
diabetes or gall bladder stones (Ludwig, 1980). 
Nonalcoholic fatty liver disease (NAFLD) is divided into two histological forms; the 
simple form is nonalcoholic fatty liver (NAFL) in which fat accumulates in liver cells 
without evidence of liver cell injury and inflammation, and the more severe form is 
nonalcoholic steatohepatitis (NASH) where fat accumulation is accompanied by 
liver cell injury and inflammation in the form of cell ballooning with or without 
fibrosis. Gold standard diagnosis of NAFLD is by histology, liver imaging is also a 
good diagnostic tool, both need the exclusion of other causes of liver steatosis, 
including significant alcohol consumption, viral hepatitis, hereditary disorders and 
certain medications. NAFLD has been linked to metabolic risk factors, including 
diabetes, obesity, lipid disorders and metabolic syndrome. The most common 
cause of death in patients with NAFLD is cardiovascular disease, patients with 
NASH particularly have an increased risk of liver-related mortality due to cirrhosis 
and liver cancer (Chalasani, 2012). 
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Liver enzymes Alanine Aminotransferase (ALT) and Aspartate Aminotransferase 
(AST) could be elevated in people with NAFLD. Even though they could be normal, 
they are still the most common cause of referral to the gastroenterologists and 
NAFLD remains the most common cause of elevated liver enzymes. Evidence 
showed that elevated liver enzymes in the presence of NAFLD is a risk factor for 
developing end-stage liver disease (Ekstedt, 2006). Liver enzymes are also 
correlated with metabolic syndrome and its components in people with NAFLD, a 
study in China found that persons with ultrasound-diagnosed NAFLD were more 
likely to have metabolic syndrome if they have high levels of ALT (Chen, 2007).   
While NAFLD is associated with metabolic syndrome in adults, adolescents, and 
children, population-based evidence is lacking on the relationship between 
elevated liver enzymes and the specific metabolic syndrome components, which 
could have implications for possible differences in causal etiology in adults versus 
younger patients. Similarly, also lacking are high-quality data on other potential 
correlates of NAFLD such as systemic inflammation (e.g., C-Reactive Protein), 
smoking status, physical inactivity, and other possible risk factors, and, if the 
relationships also differ by age group. The following sections describe these issues 
in more detail as the foundation of this research project.  
 
Epidemiology. Since imaging doesn’t recognize NAFL from NASH, and given the 
invasiveness of biopsy as a procedure, that renders the prevalence of NAFLD hard 
to determine. Back in 1990, an autopsy study of 351 nonalcoholic patients found 
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NAFLD changes in 18.5% of the obese and 2.7% of the lean patients (Wanless 
and Lentz, 1990). 
 In the general population worldwide, and with using different criteria for 
determining people with NAFLD, research showed that the condition is prevalent 
and is associated with obesity and insulin resistance (Lazo, 2008). In the 
participants of the Dallas Heart Study in the United States the prevalence was 31% 
by measuring fat content of the liver (Browning, 2004). Lazo and colleagues found 
the prevalence of NAFLD to be around 20% using liver ultrasonography in 
participants 20-74 years old of NHANES III (Lazo, 2013). A study used 70 living 
liver donors found steatosis in 38.5% of the participants, which was the most 
common histological finding (Tram, 2005). The prevalence was found to be higher 
in high risk groups, it reached 90% in obese patients (Machado, 2006) and 69% in 
diabetics (Leite, 2008). 
For epidemiological research, it is neither ethical nor practical to perform a liver 
biopsy for each suspected case of NAFLD, liver enzymes have been used as 
surrogate markers (Clark, 2003). Several studies aimed to assess the prevalence 
and extent of NAFLD using liver enzymes as surrogates. Clark and colleagues 
studied liver enzymes in participants 17 and older in the third NHANES 1988-1994, 
the cutoff points for elevated liver enzymes were AST > 37 U/L or ALT >40 U/L in 
men, and AST or ALT >31 U/L in women. The prevalence of elevated 
aminotransferases (AST, ALT, or both) was 7.9%, 69% of these elevations were 
not explained by viral hepatitis or significant alcohol consumption. They also found 
that men and women with unexplained elevations were more likely to have higher 
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BMI, waist circumference, triglycerides (TG) and insulin, they also were more likely 
to have type 2 diabetes and lower high density lipoprotein (HDL) (Clark, Frederick, 
Brancati & Diehl, 2003). 
Ioannoua and colleagues conducted a similar study using the continuous NHANES 
1999-2002 their cutoff values for elevated liver enzymes were AST >40 and ALT 
> 43 in men and women. The prevalence of elevated ALT, AST or both were 8.9%, 
4.9% and 9.8%, high ALT in NHANES 1999-2002 was more than double that in 
NHANES III using the same cutoff values. Elevated ALT was associated with male 
gender, Mexican American ethnicity, higher BMI, hepatitis C virus (HCV) antibody 
and alcohol consumption. Even after excluding HCV and significant alcohol 
consumption, the prevalence of high ALT was still high (7.3%) and associated with 
risk factors for NAFLD (Ioannou, 2006).  
 
Link with the metabolic syndrome. Ioannou also found in NHAES III that 
metabolic syndrome was associated with increased ALT (OR 3.3, CI, 1.4-8.0), as 
well as obesity and insulin resistance (Ioannou, 2005). In another NHANES III 
study he found that participants with elevated ALT without viral hepatitis or 
excessive alcohol consumption had a higher Framingham Risk Score (FRS) of 
CHD (Ioannou, Weiss, Boyko, Mozaffarin &Lee, 2006)  
In a nested case control study using NHNAES III to assess the relationship 
between unexplained elevations in ALT and metabolic syndrome, researchers 
found that the prevalence of elevated ALT in people with metabolic syndrome was 
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double that in those without it (OR 2.07, CI, 1.78-2.41) (Liangpunsakul &Chalsani, 
2005).  
The metabolic syndrome is defined by the NCEP: ATPIII as having three or more 
of the following: central obesity: waist circumference of greater than 102 cm in 
males and greater than 88 cm in females, hypertriglyceridemia: triglycerides level 
of 150mg/dL or greater, low HDL: less than 40 mg/dL in males and less than 50 
mg/dL in females, hypertension: blood pressure of 135/85 or higher and fasting 
blood glucose of 110 mg/dL or higher (Expert panel on detection, evaluation, and 
treatment of high blood cholesterol in adults, 2001). The International Diabetes 
Federation (IDF) and the American Heart Association/ National Heart, Lung, and 
Blood Association (AHA/NHLBI) agreed in the Joint Scientific Statement to 
harmonize the definition of metabolic syndrome in 2009. The criteria are: 
triglyceride level of 150mg/dL or greater or drug treatment for elevated 
triglycerides, HDL level of less than 40 mg/dL in men or less than 50 mg/dL in 
women or drug treatment for low HDL, systolic blood pressure greater than 135 
mm Hg and/or diastolic blood pressure greater than 85 mm Hg or drug treatment 
for hypertension, fasting blood glucose of 100 mg/dL or higher or drug treatment 
for diabetes, waist circumference has population- and country- specific definitions 
(Alberti et al., 2015). Currently, the ATP III and The AHA are the two most widely 
used definitions.   
 
Health outcomes. Liver steatosis alone without inflammation (NAFL) was thought 
to be non- progressive, the more severe form, NASH, has been linked to liver 
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cancer with or without cirrhosis (Fazel, 2016). Research attempted to better 
understand the natural history of NAFLD. A study in Sweden followed patients with 
biopsy-proven NAFLD for a mean of 13.7 years found that NASH rather than NAFL 
was more associated with reduced survival, the most common cause of death was 
cardiovascular events, followed by liver-related causes (Ekstedt, 2006). A more 
recent smaller study in France with a shorter duration showed that NAFL can 
progress to NASH, especially in the presence of metabolic risk factors (Pais, 
2013). In the United States, a group of researchers conducted a cohort study using 
the Rochester Epidemiology Project in Minnesota, patients diagnosed with NAFLD 
by imaging or histology between 1980 and 2000 were identified and their survival 
was analyzed. Results showed increased mortality compared to general 
Minnesota population, the leading cause was liver-related mortality and 
associations were age, impaired fasting glucose and liver cirrhosis (Adams, 2005). 
Hepatocellular carcinoma (HCC) is the most common primary liver cancer in the 
united states, it is the 5th most common cancer and the third leading cause of 
cancer death. risk factors include viral hepatitis and alcoholic cirrhosis (Mittal and 
El-Seraj, 2013). Research also showed that obesity (Marengo, 2016), diabetes 
(Davila, 2005) and metabolic syndrome (Welzel, 2011) are additional risk factors 
and are increasing in the United States (Flegal, 2010) and (Cowie, 2006). HCC in 
also increasing in the United States as was shown by a study using Surveillance, 
Epidemiology and End Results (SEER) registries from 1975-2005, the incidence 
tripled and the 1-year survival remains less than 50% (Altekruse, 2009). NAFLD 
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has been also linked to HCC (Ascha, 2010) and (Mittal et.al, 2015), even in the 
absence of cirrhosis (Perumpail, 2015) and (Pocha, 2015).  
 
Intervention. Treatment of NAFLD includes treating the liver disease itself in 
addition to the associated obesity, hyperlipidemia and diabetes. The mainstay of 
treatment is lifestyle modification. A randomized controlled trial found that low 
calorie diet and exercise improved liver histology, even without weight loss 
(Eckard, 2013). Another study emphasized weight loss in diabetics to reduce liver 
fat content (Peterson, 2005). Bariatric surgery has been also found to improve 
histological features of NAFLD (Taitano, 2014). Other treatments include insulin 
sensitizers like pioglitazone and antioxidants like vitamin E. pioglitazone reduces 
insulin resistance, while Vitamin E improves histology of NAFLD and reduces liver 
enzymes levels (Sanyal, 2010). 
 
Pediatric NAFLD. NAFLD is also prevalent in children and adolescents in the 
United States, it is the leading cause of liver disease in children. The disease in 
children resembles the adult form with differences in the details of fibrosis and 
inflammation in NASH patients. The diagnosis also needs liver imaging or 
histological examination. Pediatric NAFLD parallels the rise in obesity rates in 
children (Loomba, 2010).    
A study that examined natural history of NAFLD in children showed association 
with metabolic syndrome components. It also showed disease progression to 
fibrosis and even cirrhosis, and decreased survival in comparison with the general 
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population (Feldstein, 2009). A liver transplant study showed that NASH in 
childhood can progress to end-stage liver disease and it can recur in the 
transplanted liver (Alkhouri, 2016). The associated morbidities are cardiovascular, 
metabolic syndrome components, type 2 diabetes and low bone mineral density 
which leads to increased risk of fractures (Nidhi, 2016). 
To estimate the prevalence of NAFLD in children and adolescents, an autopsy 
study found it to be 9.6% in children between 2-19 year- old and reached up to 
17.3% in 15-19-year-old, it was the most common liver abnormality and reached 
38% in obese children (Schwimmer, 2006). Studies using the continuous NHANES 
used liver enzymes as surrogates of NAFLD, one (NHANES 1999-2004) found that 
8% of adolescents 12-19 years old have NAFLD, the prevalence was higher in 
Mexican American (11.5%) and lower in black (6%) (Fraser, 2008). Another study 
found that the prevalence rose from 3.9% in NHANES III to 10.7% in the 
continuous NHANES 2007-2010 in adolescents 12-19 years old. The criteria used 
for NAFLD were overweight and high ALT, with the exclusion of hepatotoxic 
medications and chronic hepatitis (Welsh, 2013).  
Treatment of pediatric NAFLD with increasing physical activity and tailoring diet to 
the patient’s individual needs showed improvement in liver histology and liver 
enzymes in children 5-18 years old (Nobili, 2008). Antioxidants and metformin 
have not been found to be more effective than placebo (Lavine, 2010).  
 In children and adolescents, metabolic syndrome has a modified definition of the 
ATP III criteria; literature defined it as having three of the following five criteria: 
triglycerides of 110 mg/dL or more, HDL of 40 or less, waist circumference on the 
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90th or above percentile for age/gender, blood glucose of 100 mg/dL or more, and 
blood pressure on the 90th or above percentile for age, height and gender. 
In NHANES 1999-2010, the prevalence of metabolic syndrome in 12-19-year-old 
was 10.6% in Hispanics, 8.4% in whites and 4.2% in blacks. The prevalence of 
high ALT >30 U/L parallels the prevalence of metabolic syndrome: 13.7% in 
Hispanics, 8.6% in Whites and 5.2% in blacks. adolescents with metabolic 
syndrome were 7.8 times more likely to have elevated ALT (DeBoer et al., 2013). 
 
Specific aims of the study. While NAFLD is associated with metabolic syndrome 
in adults and children, this study wants to explore the relationship between 
metabolic syndrome components and elevated ALT in adolescents and adults, in 
addition to other risk factors, including C-Reactive protein (CRP), uric acid, lifestyle 
factors like smoking and exercise, and education as an indicator of socioeconomic 
status and their association with elevated liver enzymes. High uric acid levels 
(higher than 7) has been shown to be associated with elevated liver enzymes and 
NAFLD in adults. Insulin resistance can lead to reduced excretion of uric acid 
through the kidneys which causes elevated levels in the blood (shih, 2012). This 
association in adolescents will be examined in our study, it is expected that uric 
acid will be associated with liver enzymes. High ALT level is expected to be 
associated with metabolic syndrome components, lower levels of exercise and 
lower education. The degree of association in adults and children are compared 
together.  
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METHODS 
Sample. The NHANES is a large, ongoing population-based surveillance program 
conducted by the National Center for Health Statistics (NCHC), a part of the 
Centers for Disease Control and Prevention (CDC) it started in early 1960s as a 
series of surveys and became a continuous study in 1999. The survey is a 
combination of questionnaire, interview, medical examination at home and in a 
mobile center and Laboratory tests. Data from NHANES provides information 
about nutrition, infection, and environmental and chronic health conditions in the 
United States. The survey uses a multistage probability sampling of the civilian 
non-institutionalized population of the United States of all ages. Detailed 
description of the sampling method and the survey could be found in the CDC 
website at the link: http://www.cdc.gov/nchc/nhanes/about_nhanes.htm. Our study 
sample (n=12,448) consists of males and non-pregnant females in NHANES 2001-
2006 ages 12 and older with valid ALT results; n=2,257 with high ALT values and 
n=10,191 with normal ALT. 
Variables. ALT was used as a surrogate marker for NAFLD (dependent variable). 
ALT is more closely related to liver fat than other liver enzymes (Schindhelm, 
2005). In our study, it was dichotomized into normal (30 U/L and lower) and 
elevated (over 30 U/L) in both children and adults. The cutoff point was used 
previously (DeBoer, 2013) and was the 97th percentile in NHANES III (Strauss, 
2000). Several independent variables were examined in the study. Demographic 
characteristics including age, sex, race, and education. Metabolic syndrome 
components based on the definition by the Joint Scientific statement in adults 20 
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and older and the modified definition in 12-19-year-old participants. Body Mass 
Index (BMI) which is weight in kilograms divided by the squared height in meters. 
In adults, BMI was categorized as normal if it was between 18.5 and 24.9, 
overweight between 25-29.9, and obese if it was 30 or greater. In 12-19 age group, 
BMI was categorized as normal if it was under the 85th percentile for age, 
overweight is between the 85th and the 95th percentiles and obese above the 95th 
percentile. Smoking status was classified into three categories: never, previous 
and current in adults 20 and older.  
C-reactive protein (CRP) is an inflammatory marker and has been linked to colon 
cancer and cardiovascular disease. The CDC/ American Heart Association 
workshop classified CRP as low risk for cardiovascular disease if it is less than1 
mg/L, average risk between 1 and 3, and high risk above 3 mg/L (Roberts, 2004). 
In our study, we classified it as normal (3 or less) and high (higher than 3). 
Homeostasis Model Assessment method (HOMA) was calculated using the 
formula: (Fasting Insulin(uU/ml) *Fasting glucose(mmol/L)/22.5), HOMA-IR with a 
score of 3.6 (the 75th percentile in our study) or higher indicates insulin resistance. 
Uric acid has been also linked with coronary heart disease. Hyperuricemia, or high 
uric acid, was categorized into normal (7mg/dL or less) or high (greater than 7 
mg/dL). Physical activity was classified based on meeting the American College of 
Sports Medicine (ACSM) recommendations for daily exercise as no exercise, 
below, or meeting ACSM recommendations. Physical activity was assessed by 
self-report in the last 30 days (Garber, 2011).  
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Metabolic syndrome components were classified into normal or high based on the 
Joint Scientific Statement definition. In 12-19 age group, waist circumference was 
divided by height in centimeters to get a waist circumference/height ratio (WHR), 
a variable that has been found to be associated with high ALT in Japanese 
Children (Ochiai, 2015) and with higher blood pressure in Chinese children (Zhang, 
2017). WHR has increased over time in United States children 2-19 years old (Li, 
2006). In our study, it was categorized into normal and elevated with the cut point 
of (0.66) which was the 90th percentile. 
Statistical analysis was done using Statistical package or Social Sciences (SPSS) 
software version 24. Chi square test was used to examine the prevalence of 
independent variables and compare them between the two groups of high versus 
normal ALT. Logistic regression was used to find variables that predict high ALT. 
statistical significance was defined as P value of 0.05 or less. 
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RESULTS 
Demographic characteristics of our study population are shown in Table 1. The 
overall prevalence of elevated ALT (i.e., surrogate for liver disease) was 18.1% 
(2257/12,448). The prevalence of high ALT varied somewhat across age groups 
and approached significance (16.3% to 19%, p=0.055). Prevalence also differed 
by race/ethnic group (p=0.063): 18.2% for Mexican American/other Hispanics, 
17.3% in Non-Hispanic Whites, and 19.4% in Non-Hispanic Blacks. Prevalence did 
not differ by sex (males, 18.3%; females, 17.7%; p=n.s). Elevated ALT rate varied 
somewhat by education group but no clear pattern emerged (p= 0.052).  
Tables 2a through 2e stratify our study population by age category to compare 
prevalence of elevated ALT. Uric acid was elevated among all those with NAFLD 
in each age group, ranging from 19.8% (12-19 yrs) to 24.2% (80 yrs and older) in 
a stepwise manner. Insulin resistance, as measured by the Homeostatic Model 
Assessment (HOMA-IR), was observed to be present in proportionally lower rates 
among participants with NAFLD compared to healthy participants in age groups 
40-59 (18.3% vs 27.8%, p=0.003), and 60-79 (20.7% vs 32.7%, p=0.007). The 
same pattern was observed in participants 80 yrs old and higher but this difference 
did not reach statistical significance. 
Table 3a describes metabolic syndrome components in 12-19 yr age group 
participants using the modified ATP III definition, and measuring waist 
circumference/height ratio instead of waist circumference alone. Persons with high 
ALT did not significantly differ from those with normal ALT with respect to the 
presence or absence of individual components. Tables 3b and 3c describe 
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metabolic syndrome components in males and females, respectively, in the age 
group of 20 years and older in relation to ALT level. The only statistically significant 
difference (p=0.007) was, unexpectedly, that 49.3% of healthy males had elevated 
fasting blood glucose compared to 41.9% in males with elevated ALT level. 
Table 4 shows results of a logistic regression model where age, sex, race/ethnicity, 
physical activity and BMI were fit as predictors of high ALT for 12-19-year-olds. 
Black participants were 1.2 times more likely to have high ALT than Mexican/Other 
Hispanic (95% CI 1.003-1.437) controlling for sex, physical activity or BMI. Age 
was also inversely associated with high ALT level with odds ratio of 0.964 (CI 
0.932-0.998) per one year of age. We also performed logistic regression in this 
age group to determine which components of Metabolic Syndrome as well uric acid 
and the HOMA-IR might predict elevated ALT. children with elevated uric acid level 
(i.e., > 7 mg/dL) had 3.46 times the risk (95% CI 2.48-4.83) of having high ALT 
compared to children with normal levels.  
For adults ages 20 and older, a regression model was fit to examine predictors of 
high ALT (Table 6), which showed that, compared to people with college 
education, those with less than ninth grade education were 1.316 times more likely 
to have high ALT (95% CI 1.026-1.689). Likewise, people who finished high school 
were 1.33 times (CI 1.005-1.675) more likely to have high ALT than those with 
college degrees. As with the younger age group, elevated uric acid was a 
significant predictor of elevated ALT (OR=3.8 95% CI 2.97-4.87) in the 20 yrs and 
older group (Table 7). Insulin resistance was significant with p value 0.014, people 
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with HOMA of less than 3.6 were less likely to have high ALT than those with 
HOMA 3.6 or greater (OR 0.71, CI: 0.54-0.93).   
DISCUSSION 
 
Prevalence of NAFLD. The prevalence of elevated ALT in our study was 18.1% 
in the total population, which, surprisingly, did not vary substantially by age group, 
race/ethnicity or sex. Prior studies using the continuous NHANES found the 
prevalence to be lower than our study in adults and children but these studies of 
adults used higher cut points. (Clark, Frederick, Brancati & Diehl, 2003; & Ioannou, 
2006). The prevalence rate in our study, however, is consistent with prevalence of 
NAFLD using better diagnostic tools like imaging (Lazo, 2013), and autopsy 
studies in children (Schwimmer, 2006).  
 
Metabolic Syndrome and NAFLD. We did not find any significant association 
between specific metabolic syndrome components and high ALT, while prior 
studies using NHANES III found that the risk of having high ALT in people with 
metabolic syndrome was double that risk in people who did not have metabolic 
syndrome (Liangpunsakul &Chalsani, 2005). We did not use metabolic syndrome 
as a whole entity, however, as we wanted to explore individual components as 
predictors of NAFLD. In multivariate logistic regression, our study did not produce 
evidence of a relationship between elevated HOMA-IR (i.e., insulin resistance) with 
elevated ALT in either age group. It is possible that the age group of ≥20 years is 
a broad of a risk group, and we will analyze narrower age groups prior to 
submission of this study for publication.  
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On the other hand, metabolic syndrome has been shown to have low sensitivity to 
detect insulin resistance in adolescents (Deboer and Gurka, 2014) which might 
explain the lack of association of metabolic syndrome individual components with 
high ALT in our study in the young age group. The lack of an association between 
insulin resistance (i.e., elevated HOMA-IR) and ALT in those older than age 20 is 
puzzling for biologic reasons. Insulin resistance explains NAFLD physiologically in 
basic science by the release of free fatty acids from the insulin resistant fat tissue 
and because of imbalance between lipid excretion and uptake by the liver cells, 
this leads to fat accumulation in the liver cells and, when inflammation is present, 
to NAFLD and NASH (Dietrich & Hellerbrand, 2014). 
Another diagnostic marker of metabolic syndrome is elevated waist circumference 
which reflects central obesity, but we did not see associations with this condition 
and elevated ALT in either age group. Central obesity is characterized by 
accumulation of both subcutaneous and visceral fat. While in adults central 
adiposity is part of the definition of the metabolic syndrome, in children, the 
modified definition of metabolic syndrome includes waist circumference that is at 
the 90th percentile for age and sex (Deboer, 2013),  Waist/height ratio is believed 
to be a better measure of central obesity in children and adolescents since it 
considers growth in both height and waist circumference, it is also valid for males 
and females without the need for separating values for each sex (Li, 2006). 
Waist/height ratio in our study was not significant in predicting ALT in the age group 
12-19 using more than one cut point.  
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Elevated Uric Acid and NAFLD. High uric acid was significantly associated with 
high ALT in all age groups, independent of metabolic syndrome components. A 
study of NHANES III participants ages 20-74 found that ultrasound -diagnosed 
NAFLD was significantly higher in people with higher uric acid levels, also, people 
with hyperuricemia were 1.4 times more likely to have NAFLD. Hyperuricemia was 
also significantly associated with elevated ALT. It is not known if the high uric acid 
is a cause or a consequence of NAFLD, however, a prospective Chinese study 
found after 3 year-follow up that people with higher basic levels of uric acid were 
more likely to develop NAFLD (Xu, 2010). An article hypothesized that fructose 
plays a role in NAFLD and metabolic syndrome (Lim, 2010). Our study extends the 
association between uric acid and ALT to children 12-19. 
 
Demographic characteristics and NAFLD. We did observe, however, that 
African-Americans were at higher risk for elevated ALT among those under 20 
years but, that in the older age group, education was inversely associated with 
elevated ALT. To the best of our knowledge, our study is the first to find an 
increased risk of high ALT as a marker of NAFLD in black adolescents. Prior 
reports have shown a lower prevalence of reported lower prevalence of NAFLD 
(and metabolic syndrome) in Blacks of all ages. (Beltran-Sanchez, 2011; Ioannou, 
2006; Deboer, 2013; & welsh, 2013). With respect to education, a Chinese study 
found a relationship between SES and NAFLD in patients hospitalized with type 2 
diabetes mellitus (Jia, 2015), patients in the lower SES were more likely to develop 
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NAFLD, had higher BMI, higher insulin resistance, and poorer general, emotional 
and mental health. 
Strengths and Limitations. Our study was conducted on a large, nationally 
representative sample of civil non-institutionalized men, nonpregnant women and 
children 12-19 in the United States consisting of validated data. However, there 
are several limitations, most notably, the cross-sectional nature of the study shows 
does not permit causal inference. Causality, of course, helps direct prevention and 
targeted screening. 
Also, we did not exclude participants with excessive alcohol use, a prominent risk 
factor of liver disease, due to a high level of missing data. Scientifically, we can 
justify this lack of exclusion based on findings from a large, longitudinal study that 
followed middle aged men and women without metabolic syndrome for average of 
6.4 years, at the end of the follow up, people with high ALT were 2.25 times more 
likely to develop metabolic syndrome regardless of age, sex, or alcohol intake 
(Schindhelm, 2007). Further, NAFLD now reflects the vast majority of chronic liver 
diseases, rising from 46.8% of all cases in 1988 to 75.1% in 2008 (Younossi, 
2011). 
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Conclusion 
 
 In a nationally representative cross-sectional study of US adolescents (12-19 yrs) 
and adults (≥20 yrs), we found that elevated uric acid was associated with a three-
fold likelihood of NAFLD in both age groups controlling for individual components 
of the metabolic syndrome. With respect to demographic characteristics, we 
observed that, in adolescents, African Americans had a significantly higher risk of 
NAFLD, but, for adults, education was inversely related to NAFLD. Unexpectedly, 
insulin resistance, as measured by elevated HOMA-IR, was inversely linked to 
NAFLD in both age groups whereas no other components of the metabolic 
syndrome were associated with liver disease.  
Our finding concerning high uric acid is consistent with an imaging-based national 
study with proven NAFLD in NAHNES III participants (Sirota et al., 2013). Since 
having high liver enzymes is the most common cause of referral to the 
gastroenterologists, these risk factors could help guide clinicians to develop 
screening protocols for their patients. NAFLD can lead to advanced liver disease 
and other sequelae like diabetes and cardiovascular disease in all ages. It is for 
these reasons that NAFLD has been described in the literature as a component of 
metabolic syndrome although it has not yet been officially included in the clinical 
definition. Of note, metabolic syndrome, when introduced by a Swedish physician 
over 80 years ago, included high uric acid as one of the characteristics (Pais, 
2009). Based on the significant association between uric acid and high liver 
enzymes in our study, and the significant association between insulin resistance 
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and NAFLD, obesity and metabolic syndrome in many other studies to date, the 
value of high uric acid triggering screening for NAFLD should continue to be 
discussed. A recommendation for future research stemming from our work would 
be to study nutritional factors that contribute to high uric acid in the US population.  
High intake of sugar-sweetened soft drinks, for example, has been associated with 
high uric acid levels in adults (Choi, 2008; Gao, 2007). Lastly, links between higher 
dietary fructose and biopsy-proven NAFLD patients have been reported (Ouyang 
et al., 2008). Fructose should be a concern in all ages, especially in children, given 
the increased consumption of products containing high fructose corn syrup. 
Further study of added sugars in the diet of US children and adults is needed to 
elucidate the relationship between fructose intake and high levels of uric acid, 
which, ultimately, can help increase awareness among people, provide evidence- 
based guidelines for health care providers, and provide a solid ground for change 
in food policy. 
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Table 1: Demographic characteristics of the study population by NAFLD status in NHANES 2001-
2006 (n=12448) 
 
 NAFLD 
n=2257 
(18.1%) 
 
Healthy 
n=10191 
(81.9%) 
 
P value 
Age Group (n, %) 
 
12-19  
 
20-39  
 
40-59  
 
60-79  
 
>=80  
 
 
867 (18.3%) 
 
582 (19.0%) 
 
494 (16.5%) 
 
252 (19.3%) 
 
62 (16.2%) 
 
 
3847 (81.7%) 
 
2479 (81.0%) 
 
2494 (83.5%) 
 
1050 (80.6%) 
 
321 (83.8%) 
 
 
0.055 
 
Sex 
Male (n=7195) 
 
Female (n=5281) 
 
1317 (18.3%) 
 
940 (17.8%) 
 
5878 (81.7%) 
 
4341 (82.2%) 
 
 
 
0.558 
Race/ethnicity (n, %) 
 
Mexican-Am./Other 
Hisp. 
 
Non-Hispanic white 
 
Non-Hispanic Black 
 
 
643 (18.2%) 
 
913 (17.3%) 
 
617 (19.4%) 
 
 
2881 (81.8%) 
 
4343 (82.7%) 
 
2563 (80.6%) 
 
 
 
0.063 
Education (n, %) 
 
College and above 
 
Some College 
 
High school 
 
9-11 grade 
 
< 9 grade 
 
 
293 (18.9%) 
 
357 (16.6%) 
 
366 (19.7%) 
 
210 (17.9%) 
 
162 (16.3%) 
 
 
1256 (81.1 %) 
 
1796 (83.4%) 
 
1491 (80.3%) 
 
962 (82.1%) 
 
831 (83.7%) 
 
 
0.052 
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Table 2 a: NAFLD-related risk factors in NHANES 2001-2006, age 12-19 
 
 NAFLD  
(n=867) 
Healthy 
(n=3847) 
P value 
CRP 
 
Normal  
 
Elevated 
 
 
 
795 (99.6%) 
 
3 (.04%) 
 
 
3491 (99.6%) 
 
15 (0.4%) 
 
 
 
0.831 
Uric acid 
 
Normal (n, %) 
 
Elevated (n, %) 
 
 
695 (80.2%) 
 
172 (19.8%) 
 
 
3536 (91.9%) 
 
311 (81%) 
 
 
< 0.001 
 BMI 
 
Normal 
 
Overweight  
 
Obese 
 
 
559 (65.9%) 
 
136 (16%) 
 
153 (18%) 
 
 
2445 (65.5%) 
 
594 (15.9%) 
 
691 (18.5) 
 
 
 
0.948 
Smoking 
 
Never 
 
Former 
 
Current 
 
 
 
 
NA 
 
 
 
 
NA 
 
 
 
 
NA 
Physical 
activity 
 
None 
 
Below ACSM 
guidelines 
 
Met ACSM 
guidelines 
 
 
 
144 (16.6%) 
 
402 (46.4%) 
 
 
321 (37.0%) 
 
 
 
613 (15.9%) 
 
1759 (38.3%) 
 
 
1475 (38.3%) 
 
 
 
 
0.746 
HOMA-IR 
 
Normal 
 
 
Elevated  
 
 
302 (80.3%) 
 
 
74 (19.7%) 
 
 
1338 (79.6%) 
 
 
343 (20.4%) 
 
 
 
0.752 
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Table 2 b: NAFLD-related risk factors in NHANES 2001-2006, age 20-39 
  
NAFLD  
n= 582 
 
Healthy 
n= 2479 
 
P value 
CRP 
 
Normal  
 
Elevated 
 
 
534 (98.9%) 
 
6 (1.1%) 
 
 
2291 (98.5%) 
 
34 (1.5%) 
 
 
 
   0.531 
Uric Acid 
 
Normal 
 
Elevated  
 
 
460 (79%) 
 
122 (21%) 
 
 
2291 (92.4%) 
 
188 (7.6%) 
 
 
 
   < 0.001 
 
BMI 
 
Normal 
 
Overweight  
 
Obese 
 
 
 
218 (38.7%) 
 
172 (30.5%) 
 
174 (30.9%) 
 
 
 
1003 (41.4%) 
 
755 (31.2%) 
 
644 (27.4%) 
 
 
 
 
    0.241 
Smoking 
 
Never 
 
Former 
 
Current 
 
 
311 (53.5%) 
 
68 (11.7%) 
 
202 (34.8) 
 
 
1442 (58.2%) 
 
303 (12.2%) 
 
734 (29.6%) 
 
 
 
 
    0.051 
Physical 
activity 
 
None 
 
Below ACSM 
guidelines 
 
Meeting ACSM 
guidelines 
 
 
 
181 (31.1%) 
 
302 (51.9%) 
 
99 (17%) 
 
 
 
 
 
 
822 (33.2%) 
 
1217 (491%) 
 
440 (17.7%) 
 
 
 
 
 
    0.473 
HOMA-IR 
 
Normal 
 
Elevated  
 
 
211 (81.2%) 
 
49 (18.8%) 
 
 
914 (82.6%) 
 
193 (17.4 %) 
 
 
 
 
     0.592 
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Table 2 c: NAFLD-related risk factors in NHANES 2001-2006, age 40-59 
  
NAFLD  
n=494 
 
Healthy 
n= 2493 
 
P value 
CRP 
 
Normal 
 
Elevated  
 
 
456 (98.1%) 
 
9 (1.9%) 
 
 
2356 (98.9%) 
 
26(1.1%) 
 
 
  0.131 
 
Uric Acid 
 
Normal 
 
Elevated 
 
 
 
383 (77.5%) 
 
111 (22.5%) 
 
 
 
2280 (91.5%) 
 
213 (8.5%) 
 
 
 
  < 0.001 
BMI 
 
Normal 
 
Overweight 
 
Obese 
 
 
133 (27.5%) 
 
170 (35.1%) 
 
181 (37.4%) 
 
 
621 (25.6%) 
 
915 (37.7%) 
 
889 (36.7%) 
 
 
 
   0.512 
Smoking 
 
Never 
 
Former 
 
Current 
 
 
224 (45.3%) 
 
118 (23.9%) 
 
152 (30.8) 
 
 
1175 (47.2%) 
 
303 (12.2%) 
 
734 (29.6%) 
 
 
 
 
   0.388 
Physical activity 
 
None 
 
Below ACSM 
guidelines 
 
Meeting ACSM 
guidelines 
 
 
219 (44.3%) 
 
206 (41.7%) 
 
 
69 (14%) 
 
 
1017 (40.8%) 
 
1112 (44.6%) 
 
 
365 (14.6%) 
 
 
 
   0.339 
 
HOMA-IR 
 
Normal 
 
Elevated 
 
 
 
187 (81.7%) 
 
42 (18.3%) 
 
 
 
811 (72.2%) 
 
312 (27.8%) 
 
 
 
 
   0.003 
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Table 2 d: NAFLD-related risk factors in NHANES 2001-2006, age 60-79 
  
NAFLD 
n= 252 
 
Healthy 
n= 1050 
 
P value 
CRP 
 
Normal 
 
Elevated  
 
 
242 (97.6%) 
 
6 (2.4%) 
 
 
964 (97.1%) 
 
29 (2.9%) 
 
 
  0.670 
Uric Acid 
 
Normal  
 
Elevated 
 
 
199 (79%) 
 
53 (21%) 
 
 
978 (93.1%) 
 
72 (6.9%) 
 
 
 
  < 0.001 
BMI 
 
Normal 
 
Overweight  
 
Obese 
 
 
66 (27.4%) 
 
101 (41.9%) 
 
74 (30.7%) 
 
 
254 (25.3%) 
 
447 (44.5%) 
 
304 (30.2%) 
 
 
 
 
  0.725 
Smoking 
 
Never 
 
Former  
 
Current 
 
 
80 (31.9%) 
 
123 (49%) 
 
48 (19.1 %) 
 
 
304 (29%) 
 
561 (53.5%) 
 
181 (17.5%) 
 
 
 
 
 
  0.443  
Physical activity 
 
None 
 
Below ACSM 
guidelines 
 
Meeting ASCM 
guidelines 
 
 
121 (48%) 
 
28 (19%) 
 
 
52 (20.6%) 
 
 
502 (47.8%) 
 
371 (35.3%) 
 
 
177 (16.9%) 
 
 
 
 
  0.275 
HOMA-IR 
 
 
Normal 
 
 
Elevated 
 
 
 
92 (79.3%) 
 
 
24 (20.7%) 
 
 
 
125 (67.3%) 
 
 
161 (32.7%) 
 
 
 
 
 
  0.007 
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Table 2e: NAFLD-related risk factors in NHANES 2001-2006, age 80 and older  
  
NAFLD 
n= 62 
 
 
Healthy 
n=321 
 
 
P-
Value 
 
CRP 
 
Normal 
 
Elevated  
 
 
 
53 (100%) 
 
0 (0%) 
 
 
 
296 (98%) 
 
6 (2%) 
 
 
 
  0.598 * 
  
Uric Acid 
 
Normal 
 
Elevated 
 
 
 
47 (75.8%) 
 
15 (24.2%) 
 
 
 
292 (91%) 
 
29 (9%) 
 
 
 
  0.001 
BMI 
 
Normal 
 
Overweight 
 
Obese 
 
 
22 (44%) 
 
16 (32%) 
 
12 (24%) 
 
 
106 (391%) 
 
128 (47.2%) 
 
37 (13.7%) 
 
 
 
  0.067 
Smoking 
 
Never  
 
Former 
 
Current 
 
 
19 (30.6%) 
 
36 (58.1%) 
 
7 (11.3%) 
 
 
121 (37.9%) 
 
183 (57.4%) 
 
15 (4.7%) 
 
 
 
  0.097 
Physical activity 
 
None 
 
Below ACSM 
 
Meeting ACSM 
 
 
39 (62.9%) 
 
14 (22.6%) 
 
9 (14.5%) 
 
 
168 (52.3%) 
 
99 (30.8%) 
 
54 (16.8%) 
 
 
 
  0.295 
HOMA-IR 
 
Normal 
 
Elevated  
 
 
22 (91.7%) 
 
2 (8.3%) 
 
 
125 (80.6%) 
 
30 (19.4%) 
 
 
 
0.258 * 
  
*Fisher’s exact was used because there was 1 cell count expected less than 5. 
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Table 3a: Metabolic syndrome components in NHANES 2001-2006 by NAFLD Status, ages 12-19 
 
 
 
  
MetS component NAFLD 
n= 845  
Healthy 
n= 3734 
P 
Value 
WC/height ratio 
 
Males 
Normal 
 
Elevated 
 
Females 
Normal 
 
Elevated 
 
 
 
416(96.1%) 
 
17 (3.9%) 
 
 
393 (95.4%) 
 
19 (4.6%) 
 
 
 
1843 (95.5%) 
 
78 (4.1%) 
 
 
1697 (93.6%) 
 
116 (6.4%) 
 
 
 
 
0.898 
 
 
 
0.170 
HDL 
 
 
Males 
Low 
 
Normal 
 
 
Females 
Low 
 
Normal 
 
 
 
 
77 (21.6%) 
 
279 (62.5%) 
 
 
 
42 (12.5%) 
 
294 (87.5%) 
 
 
 
 
380 (23.6%) 
 
1227 (76.4%) 
 
 
 
207 (13.7%) 
 
1307 (86.3%) 
 
 
 
 
 
0.416 
 
 
 
 
 
0.569 
Triglycerides 
 
Males 
Normal 
 
Elevated 
 
 
Females 
Normal 
 
Elevated 
 
 
 
152 (76.4%) 
 
47 (23.6%) 
 
 
 
154 (85.6%) 
 
26 (14.4%) 
 
 
 
686 (77.3%) 
 
202 (22.7%) 
 
 
 
638 (80.2%) 
 
158 (19.8%) 
 
 
 
 
0.792 
 
 
 
 
 
0.094 
Fasting Glucose 
 
Males 
Normal 
 
Elevated 
 
 
Females 
Normal 
 
Elevated 
 
 
 
167 (81.9%) 
 
37 (18.1%) 
 
 
 
174 (94.1%) 
 
11 (5.9%) 
 
 
 
728 (81.1%) 
 
170 (18.9%) 
 
 
 
742 (91.7%) 
 
67 (8.3%) 
 
 
 
 
0.793 
 
 
 
 
0.286 
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Table 3b: metabolic Syndrome Components in NHANES 2001-2006, Males 20 years and older 
MetS Components  
NAFLD 
n=825 
 
Healthy 
n= 4283 
 
P value 
Fasting Blood 
Glucose 
 
Normal <100 mg/dL 
 
Elevated>=100 
mg/dL 
 
 
232 (58.1%) 
 
167 (41.9%) 
 
 
928 (50.7%) 
 
904 (49.3%) 
 
 
 
0.007 
Waist 
Circumference 
 
Normal 
 
Elevated 
 
 
 
475 (57.6%) 
 
350 (42.4%) 
 
 
 
2185 (59.3%) 
 
1498 (40.7%) 
 
 
 
0.335 
Triglycerides 
 
 
Normal  
 
Elevated  
 
 
 
261 (66.2%) 
 
133 (33.8%) 
 
 
 
 
1125 (61.7%) 
 
699 (38.3%) 
 
 
 
 
 0.090 
HDL 
 
Low 
 
Normal 
 
 
23 (30.7) 
 
52 (69.3%) 
 
 
100 (27.8%) 
 
260 (72.2 %) 
 
 
 
0.613 
Blood pressure 
 
Normal 
 
 
Elevated 
 
 
473 (62.9%) 
 
 
279 (37.1%) 
 
 
2105 (63%) 
 
 
1236 (37.0%) 
 
 
 
 
0.951 
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Table 3c: Metabolic Syndrome Components in NHANES 2001-2006, Females 20 years and older 
 
MetS Component 
 
NAFLD 
n= 493 
 
Healthy 
n= 2335 
 
P 
value 
 
Fasting Blood Glucose 
 
Normal 
 
Elevated 
 
 
 
181 (76.4%) 
 
56 (23.6%) 
 
 
 
815 (75%) 
 
272 (25%) 
 
 
 
 
0.652 
Waist Circumference 
 
Normal 
 
 
Elevated 
 
 
202 (41%) 
 
 
291 (59%) 
 
 
970 (41.5%) 
 
 
1365 (58.5%) 
 
 
 
0.816 
Triglycerides 
 
Normal 
 
Elevated 
 
 
170 (72.6%) 
 
64 (27.4%) 
 
 
824 (77.3%) 
 
242 (22.7%) 
 
 
 
0.129 
HDL 
 
Low 
 
 
Normal 
 
 
16 (36.4%) 
 
 
28 (63.6%) 
 
 
89 (34.8%) 
 
 
167 (65.2%) 
 
 
 
 
0.837 
Blood pressure 
 
 
Normal  
 
Elevated 
 
 
 
 
339 (77.9%) 
 
96 (22.1%) 
 
 
 
 
 
1630 (80.9%) 
 
384 (19.1%) 
 
 
 
 
0.153 
 
 
 
 
 
 
 
30 
 
Table 4: Logistic model of demographic predictors of ALT >30, age 12-19 
 
predictor 
 
OR 
 
95% CI 
 
P 
value 
Sex 
Females (ref) 
Males 
 
 
0.96 
 
 
(0.823-1.12) 
 
 
0.6 
 
Age 
 
0.96 
 
(0.93-0.99) 
 
0.036 
Race/ethnicity 
Hispanic (ref) 
White 
Black 
 
 
0.96 
 
1.2 
 
 
(0.8-1.16) 
(1.003-1.437) 
 
 
0.68 
0.047 
BMI 
Normal (ref) 
Overweight 
obese 
 
0.999 
0.953 
 
(0.808-1.235) 
(0.779- 1.167) 
 
0.99 
Exercise 
Meeting ACSM (ref) 
None 
Below ACSM 
 
 
0.98 
0.909 
 
 
(0.785-1.223) 
(0.722-1.145) 
 
 
0.86 
0.42 
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Table 5: Logistic model of metabolic syndrome components as predictors of ALT>30, age 12-19 
 
Predictor 
 
OR 
 
95% CI 
 
P value 
HDL 
>=40 (ref) 
<40 
 
 
1.114 
 
 
(0.79-1.57) 
 
 
0.53 
TG 
<=110 (ref) 
>110 
 
 
0.94 
 
 
(0.673-1.3) 
 
 
0.69 
HOMA-IR 
< 3.6 (ref) 
>= 3.6 
 
 
1.14 
 
 
 
(0.82-1.61) 
 
 
0.427 
Uric Acid 
<7 (ref) 
>=7 
 
 
3.46 
 
 
(2.48-4.83) 
 
 
<0.001 
Waist/height 
ratio 
<0.66 (ref) 
>=0.66 
 
 
1.038 
 
 
(0.57-1.89) 
 
 
0.904 
Fasting glucose  
<100 (ref) 
>=100 
 
 
0.838 
 
 
(0.57-1.24) 
 
 
0.377 
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Table 6: Logistic model of demographic predictors of ALT> 30, age 20 and older 
 
Predictor 
 
OR 
 
95% CI 
 
P value 
 
Age 
 
0.998 
 
(0.994-1.002) 
 
0.266 
Sex 
Females (ref) 
Males 
 
 
1.103 
 
 
(0,996-1.259) 
 
 
0.147 
Physical activity 
Meeting ACSM guidelines (ref) 
None 
Below guidelines 
 
 
0.943 
0.957 
 
 
(0.821-1.085) 
(0.797-1.15) 
 
 
0.413 
0.64 
BMI 
Normal (ref) 
Overweight  
Obese  
 
 
0.935  
1.069 
 
 
(0.805-1.087) 
(0.919-1.3) 
 
 
0.382 
0.384 
Race/ethnicity 
Hispanic (ref) 
White 
Black  
 
 
0.922 
1.053 
 
 
(0.787-1.080) 
0.876-1.265) 
 
 
0.254 
0.584 
Education 
College or higher (ref) 
Some college 
High school 
9-11 grade 
Less than 9th grade 
 
 
1.32 
1.068 
1.33 
1.106 
 
 
(1.026-1.689) 
(0.845-1.351) 
(1.055-1.675) 
(0.86-1.413) 
 
 
0.031 
0.58 
0.016 
0.418 
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Table 7: metabolic syndrome components and other variables as predictors of ALT>30, age 20 and 
older 
 
 
 
 
 
Predictor 
 
OR 
 
95% CI 
 
P 
value 
Blood pressure 
Normal (ref) 
At risk (>130/90) 
 
 
1.008 
 
 
(0.812-1.25) 
 
 
0.943 
Triglycerides 
Normal (ref) 
High >150 
 
 
1.022 
 
 
(0.822-1.269) 
 
 
0.847 
Glucose 
<100 (ref) 
>= 100 
 
 
0.881 
 
 
(0.708-1.094) 
 
 
0.251 
Waist circumference 
Normal (ref) 
High (>102 cm in men 
and >88 cm in 
women) 
 
 
1.103 
 
 
(0.898-1.354) 
 
 
0.352 
HOMA-IR 
< 3.6 (ref) 
>=3.6  
 
 
0.709 
 
 
(0.54-0.932) 
 
 
0.014 
Uric acid 
< 7 (ref) 
>= 7  
 
 
3.8 
 
 
(2.98-4.87) 
 
 
<0.001 
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